Abstract

Obstructive sleep apnea (OSA) and depression are highly comorbid. Immune alterations, oxidative stress or microbiota dysfunction have been proposed as some mechanisms underlying this association. The aim of the proposed study is to assess the severity and profile of OSA and depressive symptoms in the context of serum microbiota metabolites, biomarkers of intestinal permeability, inflammation and oxidative stress in adult patients diagnosed with OSA syndrome. The study population consists of 200 subjects. An apnoea-hypopnoea index ≥ 5/hour is used for the diagnosis. Depressive symptoms are assessed with Beck Depression Inventory. Measured serum markers are: tumour necrosis factor–alpha and interleukin-6 for inflammation, total antioxidant capacity and malondialdehyde concentration for oxidative stress, zonulin, calprotectin, lipopolisaccharide-binding protein and intestinal fatty acids-binding protein for intestinal permeability. All of the above will be measured by enzyme-linked immunosorbent assay (ELISA). Associations between clinical symptoms profile and severity and the above markers levels will be tested. It would be valuable to seek for overlap indicators of depression and OSA to create this endophenotype possible biomarkers and form new prophylactic or therapeutic methods. The results may be useful to establish a subpopulation of patients sensitive to microbiota therapeutic interventions (probiotics, prebiotics, and microbiota transplantation).

Highlights

  • Metabolic disorders and depression are among the most disabling and common diseases worldwide

  • Metabolic disorders are in particular closely associated with obstructive sleep apnoea (OSA) syndrome (OSAS) which is a chronic disorder characterized by intermittent hypoxia during sleep with re-oxygenation injury [5,6]

  • The aim of the study is the assessment of intestinal permeability, SCFAs levels, inflammation and OxS parameters depending on both the level of depressive symptoms and OSA severity in, both obese and non-obese, patients diagnosed with OSAS

Read more

Summary

Introduction

Metabolic disorders (metabolic syndrome with its complications and comorbidities) and depression are among the most disabling and common diseases worldwide They often coexist with each other increasing mortality risk [1]. A meta-analysis confirmed a reciprocal link between depression and obesity [2] Another disorder that is strictly connected with both metabolic problems and depression is obstructive sleep apnoea (OSA). OSA is currently -regarded as an additional factor contributing to the pathogenesis of obesityrelated comorbidities [8] Multiple comorbid conditions such as metabolic complications (e.g., obesity, cardiovascular risk factors, ischemic heart disease and atrial fibrillation, impaired lipid levels, insulin resistance or type 2 diabetes mellitus and non-alcoholic fatty liver disease (NAFLD)), insomnia, depression (up to 35% [9]) or accelerated aging are prevalent in individuals with OSA [3,5,10–13].

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call